

## Dates to Remember

### Canadian Health Food Association Expo West 2008

April 3-6th, 2008

Vancouver, B.C.

[www.chfa.ca](http://www.chfa.ca)

### 2008 Sanofi-Aventis BioTalent Challenge

Edmonton: *Wednesday, April 16th*  
@ University of Alberta, TIMMs Centre

Calgary: *Wednesday, April 23rd*  
@ University of Calgary, Health Sciences Centre

[www.sanofibiotalentchallenge.ca](http://www.sanofibiotalentchallenge.ca)

### Ag-West Bio: Metabolic Syndrome (Pre-Diabetes)

April 24-25th, 2008

Saskatoon, SK

[www.agwest.sk.ca/events/IHH08/IHH08-workshop.htm](http://www.agwest.sk.ca/events/IHH08/IHH08-workshop.htm)

### Fifth Annual World Congress on Industrial Biotechnology & Bioprocessing


April 27-30th, 2008

Chicago, Illinois

[www.bio.org](http://www.bio.org)

## Recent News

### Aggregate Alberta Agrivalue Investment as at Feb 29-08



### SemBioSys' GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil

TSX symbol: SBS

CALGARY, March 14 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.

(TSX: SBS - News), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Arcadia Biosciences, Inc., made an important step forward in the commercialization of High GLA Safflower Oil. Arcadia entered into an exclusive global alliance with Bioriginal Food and Science Corp., to market and distribute High GLA Safflower Oil, an omega-6 polyunsaturated fatty acid with proven health benefits, as a nutritional supplement and

[Continued on Page 2](#)

[Cont. on Page 2](#)

**BioFinance 2008**

May 6-8, 2008

Toronto, Ontario

[www.biofinance.ca](http://www.biofinance.ca)

**CVCA 2008 Annual Conference**

May 28-30th, 2008

Montreal

[www.cvca.ca/](http://www.cvca.ca/)

**AFMNET'S Fourth Annual Scientific Conference**

May 31-June 1st, 2008

Vancouver, B.C.

[www.afmnet.ca](http://www.afmnet.ca)

**2008 TechConnect Summit**

June 3-5th, 2008

Boston, MA

[www.techconnect.org/Summit2008/](http://www.techconnect.org/Summit2008/)

**Bio International Convention**

June 17-20th, 2008

San Diego, California

[www.bio2008.org](http://www.bio2008.org)

**IFT Annual Meeting & Food Expo**

June 28-July 1st, 2008

New Orleans

[www.am-fe.ift.org/cms/](http://www.am-fe.ift.org/cms/)

**Banff Conference on Plant Metabolism**

July 30-August 3rd, 2008

Banff, AB

[www.ucalgary.ca/plantmetabolism](http://www.ucalgary.ca/plantmetabolism)

Cont. on Page 3

food ingredient. SemBioSys was contracted by Arcadia to utilize Arcadia's proprietary genes and SemBioSys' promoters and safflower transformation technology to produce and deliver safflower seed lines containing more than 40 percent GLA. Under the agreement, SemBioSys receives milestone payments upon the successful scale-up of GLA safflower lines as well as royalties from commercial sales.

GLA (gamma linolenic acid) is an omega-6 polyunsaturated fatty acid which, along with omega-3 fatty acids, has demonstrated health benefits. GLA's clinically-validated benefits include anti-inflammatory effects and improved skin health and appearance. Existing commercial sources of GLA, evening primrose oil and borage oil, contain 10 or 20-23 percent GLA, respectively. With a GLA content of 40 percent, Arcadia's high-GLA safflower oil would significantly reduce the daily consumption of GLA oil capsules and make it more convenient and affordable for consumers. According to ICIS Chemical Business Americas, the U.S. market for GLA oils is currently valued at more than US\$100 million. With a more convenient, more highly concentrated source of GLA, Arcadia believes the market can grow beyond this figure.

"Nutritional supplements and nutraceuticals are a growing market as health conscious consumers are increasingly choosing to augment their diet with nutrients that have proven health benefits. Arcadia's high-GLA safflower oil is a convenient and cost-effective source of GLA compared to existing alternatives," said Andrew Baum, President and CEO of SemBioSys.

## SemBioSys Receives European Patent

March 13 /CNW/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has been granted European patent EP0986309(B1) entitled "Uses of Oil Bodies". The patent has been issued to SemBioSys, which has exclusively licensed commercial rights associated with the patent to Botaneco Specialty Ingredients Inc.

Continued on Page 3

**ABIC 2008**

August 24-27th, 2008

Cork, Ireland

[www.abic.ca/abic2008/index.html](http://www.abic.ca/abic2008/index.html)

News Cont.

(Botaneco), its wholly owned subsidiary. The claims of European Patent EP0986309(B1) are broadly directed to the production of emulsions comprising oleosomes extracted from any living cell, including plants such as safflower, and the use of these emulsions in a wide range of commercial applications including food ingredient, personal care and over-the-counter as well as pharmaceutical applications.

“This patent demonstrates our commitment to diligently protect our proprietary oleosome technology. It provides broad coverage for the production of personal care, topical OTC and pharmaceutical, food and other products based on emulsions comprised of oleosomes in the European market,” said Andrew Baum, President and CEO of SemBioSys. “The issuance of this patent further validates our leadership in the use of oilbodies in personal care and other topical applications. We plan to launch Hydresia(TM), Botaneco’s first oleosome based ingredient, in Europe this spring after a successful launch in the U.S. and Canada last year.” Counterparts to the European patent EP0986309(B1) have issued in many jurisdictions worldwide including the United States, Canada, Australia, Japan, China, India and Mexico.

In September of 2007, Botaneco commissioned its new 10,000 square foot, state-of-the-art commercial manufacturing facility for the production of its all natural oleosome base emulsion for the personal care and cosmetic markets. Botaneco recently announced that its first international brand customer, Burt’s Bees, launched three personal care products in the U.S. using Botaneco’s Hydresia(TM) ingredient.

## Science Policy: Positioning Canada for a Vibrant Future

Join

DR. HOWARD ALPER

Distinguished University Professor, University of Ottawa & Chair, Science, Technology and Innovation Council of Canada

Thursday March 27, 7:30 pm

[Continued on Page 4](#)

### **Science Policy: Positioning Canada for a Vibrant Future**

Featuring an opening talk by Dr. Alper; welcoming remarks from Eric Newell (Chancellor University of Alberta and former CEO Syncrude Canada Ltd.); and a discussion with Peter Hackett (President and CEO Alberta Ingenuity) and Bob Fessenden (Deputy Minister of Alberta Advanced Education and Technology).

Telus Centre Auditorium, 112 Street - 87 Avenue

Refreshments to follow

*Dr. Howard Alper is a respected member of the science community both nationally and internationally. His research spans organic and inorganic chemistry, with applications in the pharmaceutical, petrochemical, and commodity chemical industries. He has over 500 publications and 37 patents.*

*Dr. Alper has served as Chair of the Board of Governors of the Council of Canadian Academies and on private-sector boards. Major awards include the Gerhard Herzberg Canada Gold Medal in Science and Engineering, the Steacie Award for Chemistry, the Urgel Archambault Prize, the Montreal Medal, and the Chemical Institute of Canada Medal. Dr. Alper is an Officer of the Order of Canada. Dr. Alper's visit made possible by the generous support of: 75th CSC Lecture Series; Syncrude Canada Ltd.; CIC Edmonton Section; Department of Chemistry; WISEST.*

### **Cold-Fx® Explores Children's Market: Cv Technologies Releases Positive Safety Results Of Pilot Clinical Trial As First Step**

Edmonton, AB (CVQ – TSX) CV Technologies announced positive safety results in a pilot clinical trial as the first step in developing a children's formulation of COLD-fx® - the # 1 selling cold and flu remedy in Canada.

The randomized, double-blind, placebo-controlled study was designed to measure the safety and tolerability of COLD-fx for treatment of cold and flu in children. Acute three-day doses of COLD-fx were well tolerated with

no serious adverse events, or differences in adverse events versus the placebo group. The research was also successful in determining effect size, which enables appropriate statistical planning of a potential efficacy study.

“There is clearly a great need and substantial market for a safe and effective product to treat cold and flu in children, who suffer from these ailments much more often than adults,” said Jacqueline Shan, PhD, DSc, President, CEO and Chief Scientific Officer of CV Technologies. “While further clinical studies are needed before COLD-fX can be recommended for those under 12, the results of our research are promising for development of a children’s formulation. We are evaluating plans for the next stage of our pediatric research, as one element of our strategy to expand our product pipeline.”

Seventy-five children between the ages of three and 12 were recruited in Edmonton for the study, which was conducted in the winter of 2005-2006. Of those children, 46 developed an upper respiratory tract infection (URTI) and they were randomly assigned to receive acute three-day treatment with either a placebo or COLD-fX (two weight based dosage levels).

The trial was approved by Health Canada and the University of Alberta Ethics Committee and conducted in collaboration with pediatric researchers in the Faculty of Medicine at the University of Alberta, Edmonton, Canada. The findings were presented at two major scientific conferences, including the Annual Symposium on Complementary Health Care in Exeter, England, the longest running conference in its field.

This is the first time COLD-fX, a naturally derived extract of North American Ginseng, has been studied for use in children. It comes at a time when Health Canada and the FDA in the U.S. are reviewing the dosage and efficacy of roughly 800 children’s cough and cold remedies, particularly for children under the age of six. A recent study by the Centers for Disease Control and Prevention (CDC) says over 7,000 children under 12 are treated each year in U.S. hospital emergency rooms for adverse drug reactions from cough and cold medications.